100.23 USD
↗ 6.11 (6.49%)AT CLOSE (11:59 AM EDT)
Spyre Therapeutics, Inc. Common Stock
SYRENASDAQ • USD
100.27
↗ 0.03 (0.03%)
POST MARKET (AS OF 05:07 PM EDT)
Post Market
AS OF 05:07 PM EDT
100.27
↗ 0.03 (0.03%)
Market: OPEN
Shares of Spyre Therapeutics, Inc. Common Stock (SYRE) are trading at $104.57. The technical outlook is "Strong Buy" and the fundamental picture shows "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Jul 17, 2026.
Open?$94.26
High?$101.36
Low?$92.37
Prev. Close?$94.12
Volume?1.1M
Avg. Volume?1.7M
VWAP?$98.75
Rel. Volume?0.64x
Bid / Ask
Bid?$85.38 × 100
Ask?$114.15 × 100
Spread?$28.77
Midpoint?$99.77
Valuation & Ratios
Market Cap?8.2B
Shares Out?87.9M
Float?66.9M
Float %?85.2%
P/E Ratio?N/A
P/B Ratio?12.18
EPS?-$1.71
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Address
221 CRESCENT STREET
WALTHAM, MA 02453
Phone: (617) 651-5940
WALTHAM, MA 02453
Phone: (617) 651-5940
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?50
Short Sent.?46
Piotroski F-Score?0/9Weak
Altman Z-Score?50.48Safe
Confidence?49%Low
Short InterestSqueeze Risk
Short % of Float?20.40%Squeeze Risk
Short Interest?13.6M
Days to Cover?5.6
Free Float66.9M
Avg Daily Volume2.5M
Settlement Date2026-06-30
Financial Health
Current Ratio?8.97Strong
Quick Ratio?8.97Strong
Cash Ratio?1.14Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?12.18HIGH▾
Peers100
S&P16
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-33.4CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-22.2%WEAK▾
S&P7
ROA?-19.5%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?N/A
Enterprise Value?$8.1B
Fundamentals ratios updated end of day